Skip to content
DataLookout
Menu

NCT06677190

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 30, 2026 to Dec 31, 2027 Show 7 more changesShow less
    • Eligibility criteria expanded, about 52 words
    • Enrollment closed, study ongoing
    • Study completion pushed from Jun 30, 2029 to Jun 30, 2030
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study description revised
    • Site details revised at 2 of 2 sites
    • Collaborators: details revised at 1 of 1 entry
  2. Notable Eligibility criteria expanded, about 14 words
    • Study description expanded, about 12 words
    • Study title expanded, about 2 words
    v5
  3. Minor Start date: Dec 1, 2024 to Dec 20, 2024
    • Site contacts updated at 2 of 2 sites
    v4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2025 to Dec 1, 2024
    • Site details revised at 2 of 2 sites
    v3
  5. Notable Eligibility criteria expanded, about 16 wordsv2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective Response Rate (ORR)
Timeframe: ORR expected to be observed up to 3 years.
Progression Free Survival at 6 months (PFS6)
Timeframe: Disease will be evaluated at baseline and every 2 cycles on treatment, where each cycle is 4 weeks. Relevant to this endpoint is the 6 month timepoint.

Secondary (4)

Grade 4 Treatment-Related Toxicity Rate
Median Progression Free Survival (PFS)
Median Overall Survival (OS)
Clinical Benefit Rate (CBR)

Arms and interventions

BelzutifanExperimental

15 participants will be enrolled for Stage 1 and will complete: * Baseline in-clinic visit * Imaging every 2 cycles * ECG on Day 1 of each cycle * Cycle 1 through End of Treatment: * Day 1 through 28 of 28 day cycle: Predetermined dose of Belzutifan 1x daily. * Day 15 of 28 day cycle: in-clinic visit * Cycle 2 Day 15 of 28 day cycle: in-clinic visit * End of treatment visit with ECG, blood tests, and imaging. * 30 Day post-treatment visit * Long-term follow up: every 6 months for 3 years * If 3 or more participants have objective response OR 2 or more participants are progression-free at 6 months, the study will enroll an additional 14 participants for Stage 2. Otherwise, enrollment will stop if there are less than 3 participants with objective response AND less than 2 participants are progression-free at 6 months.

Drugs: Belzutifan

Sites

2 sites in 1 country